Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
CONCLUSION: In this large cohort of publicly or privately insured patients with RA in the United States, ABA was associated with a 20% reduced risk of CVD versus TNFi. While this observational study is subject to potential residual confounding, our results were consistent in patients with baseline CVD.
PMID: 29764964 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Jin Y, Kang EH, Brill G, Desai RJ, Kim SC Tags: J Rheumatol Source Type: research
More News: Abatacept | Arthritis | Cardiology | Cardiovascular | Databases & Libraries | Heart | Heart Attack | Insurance | Ischemic Stroke | Medicare | Orencia | Rheumatoid Arthritis | Rheumatology | Stroke | Study | USA Health